Physician profile
Brian Averell
NPI 1891742763
$25,589.39
in general payments reported to CMS, 2019-2025
65 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $423 · 2022: $1,486 · 2023: $4,024 · 2024: $7,367 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $3,650 · Travel and Lodging: $1,167 · Education: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,276.95 |
| Consulting Fee | $3,650.00 |
| Travel and Lodging | $1,166.85 |
| Education | $436.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $5,423.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $1,448.81 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Alexion Pharmaceuticals, INC. | $1,431.07 | 2022-2025 | Ultomiris, Soliris |
| Ucb, INC. | $1,208.38 | 2021-2025 | Briviact, Nayzilam, Zilbrysq |
| Harmony Biosciences LLC | $1,030.33 | 2023-2025 | Wakix |
| Biogen, INC. | $993.51 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Jazz Pharmaceuticals INC. | $968.93 | 2021-2025 | Xywav, Epidiolex |
| Teva Pharmaceuticals USA, INC. | $792.33 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $784.96 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $750.04 | 2022-2025 | Nuplazid, Daybue |
| Eisai INC. | $717.96 | 2022-2025 | |
| Sk Life Science, INC. | $705.04 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $675.41 | 2021-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $613.43 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Emd Serono, INC. | $611.50 | 2021-2025 | Mavenclad |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $592.82 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $579.72 | 2023-2025 | |
| Genzyme Corporation | $489.43 | 2023-2025 | |
| Inspire Medical Systems, INC. | $473.58 | 2023-2025 | Inspire |
| Lundbeck LLC | $388.14 | 2023-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $370.52 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $314.64 | 2022 | |
| Octapharma USA, INC. | $304.88 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Amgen INC. | $294.19 | 2021-2025 | Uplizna, Aimovig |
| Otsuka America Pharmaceutical, INC. | $245.18 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $244.27 | 2022-2025 | Hyqvia |
| Janssen Biotech, INC. | $196.98 | 2025 | |
| Mallinckrodt Hospital Products INC. | $196.13 | 2021-2024 | Acthar |
| Axsome Therapeutics, INC. | $178.26 | 2025 | Sunosi, Symbravo |
| Averitas Pharma INC. | $177.81 | 2023-2025 | Qutenza |
| Horizon Therapeutics Plc | $168.87 | 2021-2023 | Uplizna |
| Neurelis, INC. | $149.45 | 2022-2025 | Valtoco |
| Avadel Cns Pharmaceuticals, LLC | $142.15 | 2023-2025 | Lumryz |
| Celgene Corporation | $136.07 | 2022-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $129.02 | 2024-2025 | Ponvory |
| Grifols USA, LLC | $124.99 | 2023-2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $121.64 | 2023-2025 | Horizant, Horizant |
| Impel Pharmaceuticals LLC | $120.11 | 2024-2025 | Trudhesa |
| Sumitomo Pharma America, INC. | $112.86 | 2023 | Aptiom, Latuda |
| Xeris Pharmaceuticals, INC. | $102.94 | 2023-2025 | Keveyis |
| Csl Behring | $73.68 | 2024-2025 | Hizentra |
| Scilex Pharmaceuticals INC. | $71.93 | 2023-2024 | Ztlido |
| Avion Pharmaceuticals | $67.02 | 2022-2023 | Dhivy |
| Banner Life Sciences, LLC | $65.76 | 2022-2023 | |
| Abbott Laboratories | $65.61 | 2023 | Amplatzer Amulet |
| Supernus Pharmaceuticals, INC. | $62.46 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $58.66 | 2023-2024 | Fycompa |
| Astrazeneca Pharmaceuticals LP | $51.93 | 2021-2022 | |
| Ge Healthcare | $51.09 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $49.95 | 2023 | Rytary |
| Sandoz INC. | $48.57 | 2024 | |
| Idorsia Pharmaceuticals US INC | $44.03 | 2023-2025 | Quviviq, Quviviq |
| Tanabe Pharma America, INC. | $40.79 | 2024-2025 | Radicava |
| Biohaven Pharmaceuticals, INC. | $39.63 | 2021 | |
| Nevro Corp. | $36.83 | 2023-2024 | Senza |
| Carbofix Spine INC | $34.89 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.56 | 2022 | |
| Livanova USA, INC. | $32.09 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $26.62 | 2025 | Inbrija, Xeomin |
| Insightec,INC | $23.90 | 2025 | Exablate |
| Biohaven Pharmaceutical Holding Company LTD. | $22.19 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.09 | 2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $19.63 | 2022 | |
| Kedrion Biopharma, INC. | $19.24 | 2024 | Koate, Albuked, Kedrab |
| Cycle Pharmaceuticals INC | $19.10 | 2024 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Averell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.